111 related articles for article (PubMed ID: 22735081)
1. The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: a European perspective.
Chadda S; Larkin M; Jones C; Sykes D; Barber B; Zhao Z; Gao S; Bengttson NO
J Oncol Pharm Pract; 2013 Mar; 19(1):38-47. PubMed ID: 22735081
[TBL] [Abstract][Full Text] [Related]
2. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives.
Colwell HH; Mathias SD; Ngo NH; Gitlin M; Lu ZJ; Knoop T
J Infus Nurs; 2007; 30(3):153-60. PubMed ID: 17505216
[TBL] [Abstract][Full Text] [Related]
3. Infusion reactions: diagnosis, assessment, and management.
Vogel WH
Clin J Oncol Nurs; 2010 Apr; 14(2):E10-21. PubMed ID: 20350882
[TBL] [Abstract][Full Text] [Related]
4. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
5. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.
Kang SP; Saif MW
J Support Oncol; 2007 Oct; 5(9):451-7. PubMed ID: 18019853
[No Abstract] [Full Text] [Related]
6. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
Muallaoglu S; Disel U; Mertsoylu H; Besen A; Karadeniz C; Taner Sumbul A; Abali H; Ozyilkan O
J BUON; 2013; 18(1):261-7. PubMed ID: 23613414
[TBL] [Abstract][Full Text] [Related]
7. Hypersensitivity reactions to oxaliplatin: what nurses need to know.
Bonosky K; Miller R
Clin J Oncol Nurs; 2005 Jun; 9(3):325-30. PubMed ID: 15973843
[TBL] [Abstract][Full Text] [Related]
8. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
10. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
11. [Infusion reactions].
Sato K; Kohgo Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1671-4. PubMed ID: 18931569
[TBL] [Abstract][Full Text] [Related]
12. Panitumumab: new drug. Metastatic colorectal cancer: don't make things worse!
Prescrire Int; 2009 Aug; 18(102):157. PubMed ID: 19743571
[No Abstract] [Full Text] [Related]
13. Cetuximab-associated infusion reactions: pathology and management.
Patel DD; Goldberg RM
Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
[TBL] [Abstract][Full Text] [Related]
14. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.
Cartwright TH; Genther R
Clin Colorectal Cancer; 2008 May; 7(3):202-3. PubMed ID: 18621639
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
17. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.
Song X; Long SR; Barber B; Kassed CA; Healey M; Jones C; Zhao Z
Curr Clin Pharmacol; 2012 Feb; 7(1):56-65. PubMed ID: 22299770
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: adverse event profile and recommendations for toxicity management.
Thomas M
Clin J Oncol Nurs; 2005 Jun; 9(3):332-8. PubMed ID: 15973844
[TBL] [Abstract][Full Text] [Related]
19. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
[TBL] [Abstract][Full Text] [Related]
20. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
